00:06 , Jan 23, 2019 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: 3-D models A 3-D human tissue model that mimics beating adult myocardium could help assess the effects of heart disease therapies on myocardial contractility. Generation and use of the biomimetic model involves five steps:...
22:52 , Jan 15, 2019 |  BC Week In Review  |  Company News

AZ's Bohen departing after cancer-focused tenure

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Sean Bohen is leaving as CMO and EVP of global medicines development after a tenure marked by mixed results for the pharma's checkpoint inhibitor. Shortly after Bohen joined the pharma...
23:49 , Jan 14, 2019 |  BC Extra  |  Company News

AZ's Bohen departing after cancer-focused tenure

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Sean Bohen is leaving as CMO and EVP of global medicines development after a tenure marked by mixed results for the pharma's checkpoint inhibitor. Shortly after Bohen joined the pharma...
22:18 , Dec 26, 2018 |  BC Extra  |  Company News

FDA accepts Acer, Kala NDAs before funding lapse

FDA accepted for review NDAs from Acer Therapeutics Inc. (NASDAQ:ACER) and Kala Pharmaceuticals Inc. (NASDAQ:KALA) before the partial government shutdown blocked the agency from taking on new user fee-based applications. The agency granted Priority Review...
19:26 , Dec 21, 2018 |  BC Week In Review  |  Clinical News

Medix planning Mexican NDA for obesity candidate

Saniona AB (SSE:SANION) said partner Medix Products S.A. de C.V. (Mexico City, Mexico) plans to submit an NDA next half in Mexico for obesity candidate tesofensine (NS2330) after two doses of the compound met the...
18:36 , Nov 9, 2018 |  BC Week In Review  |  Company News

AZ looks to new medicines to drive growth

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Nov. 8 it will look to 10 new drugs to support a return to growth. The pharma reported 3Q18 product sales of $5.3 billion, up 9% at constant exchange rates...
23:40 , Nov 8, 2018 |  BC Extra  |  Company News

AZ looks to new medicines to drive growth

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Thursday it will look to 10 new drugs to support a return to growth. The pharma reported 3Q18 product sales of $5.3 billion, up 9% at constant exchange rates from...
21:54 , Oct 31, 2018 |  BC Extra  |  Company News

GSK cuts some respiratory targets, keeps others in play

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) cut three respiratory programs against targets largely ignored by the rest of the industry after all three failed to meet efficacy targets in Phase II trials. The pharma disclosed the pruning...
18:00 , Oct 19, 2018 |  BC Week In Review  |  Financial News

Led by ex-Afferent execs, CuraSen raises $54.5M series A

Neurodegenerative disease company CuraSen Therapeutics Inc. (San Mateo, Calif.) raised $54.5 million in a series A round on Oct. 17 led by New Leaf Venture Partners. Also participating were Longitude Capital, funds managed by Tekla...
17:06 , Oct 19, 2018 |  BC Week In Review  |  Financial News

Velicept raises additional $15M in series B

Velicept Therapeutics Inc. (Malvern, Pa.) raised $15 million in a series B round extension led by Samsara BioCapital. Existing investors CDK, Fountain Healthcare, Longitude Venture Partners and Becker Ventures also participated. Becker Ventures is Velicept's...